Background Advanced age-related macular degeneration (AMD) is a leading cause of
blindness. While around half of the genetic contribution to advanced AMD has been uncovered, …

Worldwide, age-related macular degeneration (AMD) is a serious threat to vision loss in
individuals over 50 years of age with a pooled prevalence of approximately 9%. For 2020, the …

Genome-wide association studies (GWAS) have identified numerous genetic variants in the
human genome associated with diseases and traits. Nevertheless, for most loci the …

DNA methylation provides a crucial epigenetic mark linking genetic variations to environmental
influence. We have analyzed array-based DNA methylation profiles of 160 human …

Genomic studies in age-related macular degeneration (AMD) have identified genetic
variants that account for the majority of AMD risk. An important next step is to understand the …

Significant association signals from genome-wide association studies (GWAS) point to
genomic regions of interest. However, for most loci the causative genetic variant remains …

Genome-wide association studies (GWAS) for late stage age-related macular degeneration (AMD)
have identified 52 independent genetic variants with genome-wide significance at 34 …

Purpose: Anti-vascular endothelial growth factor (anti-VEGF) therapies, which attenuate the
capacity of VEGF to bind to VEGF receptors, are standard-of-care options for various retinal …

Over the last 15 years, genome-wide association studies (GWAS) have greatly advanced
our understanding of the genetic landscape of complex phenotypes. Nevertheless, causal …

Purpose: To genetically characterize a subphenotype of geographic atrophy (GA) in AMD
associated with rapid progression and a diffuse-trickling appearance on fundus …